Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I:wherein variables A4, A5, A6, A8, each of R1 and R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.
Amgen Inc.
C C C A C A C C A A A C C C
C07D C07D C07D A61P C07D A61P C07D C07D A61P A61P A61P C07D C07F C07D
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Bryant Wenge Nuria A. Yuan Jian Ning Ted Jennifer R. Qingyian Robert M. Shannon Jonathan D. Patricia Wenyuan Ana Elena Qiufen
Yang Zhong Tamayo Cheng Chen Chen Judd Allen Liu Rzasa Rumfelt Low Lopez Qian Minatti Xue